The University of Chicago Header Logo

Kenneth Gordon

Title
InstitutionUniversity of Chicago
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Blauvelt A, Gordon KB, Langley RG, Branigan PJ, Chen Y, Miller M, Han C, Fakharzadeh S, Muñoz-Elías EJ, Armstrong AW. Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2. J Invest Dermatol. 2024 Jun 25. PMID: 38936766.
      Citations:    Fields:    
    2. Thapar M, Patel M, Gordon K. Bimekizumab for the treatment of psoriasis. Immunotherapy. 2024 Apr; 16(7):431-446. PMID: 38506262.
      Citations:    Fields:    Translation:HumansCells
    3. Okubo Y, de Cuyper D, Davies O, Thaçi D, Gordon KB, Langley RG, Warren RB, Rosmarin D, Lebwohl M, Peterson L, Madden C. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol. 2024 Mar 15; 190(4):477-485. PMID: 37950894.
      Citations:    Fields:    Translation:Humans
    4. Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis AF, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Thaçi D. Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52?weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024 Mar 07. PMID: 38451052.
      Citations:    Fields:    
    5. Burshtein J, Shah M, Zakria D, Lockshin B, Crowley J, Merola JF, Gordon K, Shahriari M, Korman NJ, Chovatiya R, Kalb R, Lebwohl M. The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel. Dermatol Ther (Heidelb). 2024 Feb; 14(2):323-339. PMID: 38340237; PMCID: PMC10891030.
      Citations:    
    6. Flohr C, Brandling-Bennett HA, Arkin LM, Chiu YE, Hebert AA, Callen JP, Castelo-Soccio L, Co DO, Cordoro KM, Curran ML, Dalrymple AM, Gordon KB, Hanna D, Irvine AD, Kim S, Kirkorian AY, Lara-Corrales I, Lindstrom J, Paller AS, Reyes M, Begolka WS, Tom WL, Van Voorhees AS, Vleugels RA, Lee LW, Davies O, Siegfried EC. Executive summary: Consensus treatment guidelines for the use of methotrexate for inflammatory skin disease in pediatric patients. J Am Acad Dermatol. 2024 Jun; 90(6):1271-1275. PMID: 38342248; PMCID: PMC11096036.
      Citations:    Fields:    Translation:Humans
    7. Papp KA, Gordon K, Strober B, Zhuo J, Becker B, Zhong Y, Beaumont JL, Pham TP, Kisa R, Napoli AA, Banerjee S, Armstrong AW. Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2024 Feb 01; 160(2):204-209. PMID: 38117487; PMCID: PMC10733845.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    8. Blauvelt A, Langley RG, Gordon KB, Silverberg JI, Eyerich K, Sommer MOA, Felding J, Warren RB. Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review. Dermatol Ther (Heidelb). 2023 Dec; 13(12):3031-3042. PMID: 37924462; PMCID: PMC10689637.
      Citations: 4     
    9. Ramcharran D, Strober B, Gordon K, DeKlotz C, Fakharzadeh S, Yang YW, Swerdel J, Hardin J, Dronavalli S, Paller AS. The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases. Adv Ther. 2023 11; 40(11):5090-5101. PMID: 37737889; PMCID: PMC10567878.
      Citations: 2     Fields:    Translation:Humans
    10. Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, Tsai TF, Gordon KB, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl MG. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023 10 28; 402(10412):1541-1551. PMID: 37738999.
      Citations: 8     Fields:    Translation:Humans
    11. Siegfried EC, Arkin LM, Chiu YE, Hebert AA, Callen JP, Castelo-Soccio L, Co DO, Cordoro KM, Curran ML, Dalrymple AM, Flohr C, Gordon KB, Hanna D, Irvine AD, Kim S, Kirkorian AY, Lara-Corrales I, Lindstrom J, Paller AS, Reyes M, Begolka WS, Tom WL, Van Voorhees AS, Vleugels RA, Lee LW, Davies OMT, Brandling-Bennett HA. Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines. Pediatr Dermatol. 2023 Sep-Oct; 40(5):789-808. PMID: 37316462.
      Citations: 2     Fields:    Translation:Humans
    12. Singla S, Putman M, Liew J, Gordon K. Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis - Authors' reply. Lancet Rheumatol. 2023 Jun; 5(6):e313. PMID: 38251598.
      Citations:    Fields:    Translation:Humans
    13. Strober B, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA, Thaçi D. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. Immunotherapy. 2023 08; 15(11):787-797. PMID: 37150956.
      Citations: 2     Fields:    Translation:Humans
    14. Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023 Apr; 5(4):e200-e207. PMID: 38251522.
      Citations: 5     Fields:    Translation:Humans
    15. Vu A, Maloney V, Gordon KB. Deucravacitinib in moderate-to-severe psoriasis. Immunotherapy. 2022 11; 14(16):1279-1290. PMID: 36373503.
      Citations: 1     Fields:    Translation:Humans
    16. Vu A, Ulschmid C, Gordon KB. Anti-IL 23 biologics for the treatment of plaque psoriasis. Expert Opin Biol Ther. 2022 12; 22(12):1489-1502. PMID: 36243011.
      Citations: 4     Fields:    Translation:Humans
    17. Strober B, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA, Thaçi D. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023 01; 88(1):40-51. PMID: 36115523.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    18. Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaçi D. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 07 01; 158(7):735-744. PMID: 35544084; PMCID: PMC9096693.
      Citations: 7     Fields:    Translation:Humans
    19. Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatol Ther (Heidelb). 2022 Feb; 12(2):561-575. PMID: 35050485; PMCID: PMC8850502.
      Citations: 4     
    20. Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB, Thaçi D, Puig L. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatol Ther (Heidelb). 2022 Feb; 12(2):495-510. PMID: 35025062; PMCID: PMC8850503.
      Citations: 13     
    21. Gordon KB, Lebwohl M, Papp KA, Wu JJ, Langley RG, Blauvelt A, Kaplan B, Shah M, Zhao Y, Sinvhal R, Reich K, Bachelez H. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022 03; 186(3):466-475. PMID: 34652810; PMCID: PMC9298814.
      Citations: 20     Fields:    Translation:Humans
    22. Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022 06; 149(6):2010-2020.e8. PMID: 34767869.
      Citations: 17     Fields:    Translation:Humans
    23. Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021 12; 185(6):1146-1159. PMID: 34105767.
      Citations: 15     Fields:    Translation:Humans
    24. Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L. Efficacy, safety, usability, and acceptability of risankizumab 150?mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. J Dermatolog Treat. 2022 Jun; 33(4):2085-2093. PMID: 33947295.
      Citations: 5     Fields:    Translation:Humans
    25. Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021 02 06; 397(10273):475-486. PMID: 33549192.
      Citations: 64     Fields:    Translation:Humans
    26. Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 02 06; 397(10273):487-498. PMID: 33549193.
      Citations: 58     Fields:    Translation:Humans
    27. Reich K, Armstrong AW, Foley P, Song M, Miller M, Shen YK, You Y, Han C, Gordon KB. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. Am J Clin Dermatol. 2020 Dec; 21(6):881-890. PMID: 32910434.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    28. Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. JAMA Dermatol. 2020 12 01; 156(12):1344-1353. PMID: 33052382; PMCID: PMC7557488.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    29. Gordon KB, Warren RB, Gottlieb AB, Blauvelt A, Leonardi C, Boehnlein M, Brock F, Ecoffet C, Thaçi D, Poulin Y, Reich K. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). Br J Dermatol. 2021 04; 184(4):652-662. PMID: 32652544; PMCID: PMC8247431.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    30. Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021 Feb; 84(2):432-470. PMID: 32738429.
      Citations: 58     Fields:    Translation:Humans
    31. Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, Photowala H, Longcore M, Zhan T, Foley P. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol. 2020 Dec; 34(12):2830-2838. PMID: 32320088; PMCID: PMC7818271.
      Citations: 21     Fields:    Translation:Humans
    32. Patel AD, Katz K, Gordon KB. Cutaneous Manifestations of Chronic Liver Disease. Clin Liver Dis. 2020 08; 24(3):351-360. PMID: 32620276.
      Citations: 2     Fields:    Translation:Humans
    33. Gordon KB, Crowley JJ, Korman NJ, Murphy FT, Spelman L, Yamauchi PS, Mendelsohn AM, Parno J, Rozzo SJ, Ellis CN, Reich K, Poulin Y. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. J Dermatolog Treat. 2022 Feb; 33(1):219-228. PMID: 32349565.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    34. Strober B, Gordon KB. Comparative Effectiveness Studies for Psoriasis-The Methods Matter. JAMA Dermatol. 2020 03 01; 156(3):253-255. PMID: 32022830.
      Citations:    Fields:    Translation:Humans
    35. Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020 Jun; 82(6):1445-1486. PMID: 32119894.
      Citations: 75     Fields:    Translation:Humans
    36. Armstrong AW, Blauvelt A, Crowley JJ, Gordon KB, Krueger GG, Krueger JG, Sobell JM, Strober BE, Srivastava B, Menter A. Defining drug-free remission of skin disease in patients with plaque psoriasis. Br J Dermatol. 2020 06; 182(6):1484-1487. PMID: 31705649.
      Citations: 1     Fields:    Translation:Humans
    37. Callis Duffin K, Mason MA, Gordon K, Harrison RW, Crabtree MM, Guana A, Germino R, Lebwohl M. Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. Dermatology. 2021; 237(1):46-55. PMID: 31962340; PMCID: PMC7845438.
      Citations: 11     Fields:    Translation:Humans
    38. Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J, IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020 06; 182(6):1348-1358. PMID: 31887225; PMCID: PMC7317420.
      Citations: 40     Fields:    Translation:Humans
    39. Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt A. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020 Apr; 82(4):936-945. PMID: 31809827.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    40. Gordon KB, Rosenbaum JT, Arikan D, Lau WL, Li P, Faccin F, Panaccione R, Burmester GR. Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Adv Ther. 2020 01; 37(1):364-380. PMID: 31748904; PMCID: PMC6979455.
      Citations: 28     Fields:    Translation:Humans
    41. Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul C. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2020 Feb; 34(2):301-309. PMID: 31479549; PMCID: PMC7028252.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    42. Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020 Jan; 82(1):161-201. PMID: 31703821.
      Citations: 40     Fields:    Translation:Humans
    43. Langley RGB, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M, Reich K, Nikaï E. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020 Feb; 29(2):369-380. PMID: 31655974.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    44. Song M, Li S, Jiang J, Youn SW, Tsai TF, Choe YB, Huang YH, Gordon KB, Reich K. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019 Dec; 46(12):1141-1152. PMID: 31631377.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    45. Serrano L, Maloney V, Gordon KB. Risankizumab in moderate-to-severe plaque psoriasis. Immunotherapy. 2019 11; 11(16):1357-1370. PMID: 31578912.
      Citations: 2     Fields:    Translation:Humans
    46. Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019 Sep; 81(3):775-804. PMID: 31351884.
      Citations: 39     Fields:    Translation:Humans
    47. Elewski B, Menter A, Crowley J, Tyring S, Zhao Y, Lowry S, Rozzo S, Mendelsohn AM, Parno J, Gordon K. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2020 Dec; 31(8):763-768. PMID: 31268369.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    48. Gordon KB, Armstrong AW, Foley P, Song M, Shen YK, Li S, Branigan P, Liu X, Reich K, Muñoz-Elías EJ. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019 12; 139(12):2437-2446.e1. PMID: 31207232.
      Citations: 23     Fields:    Translation:Humans
    49. Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr; 80(4):1073-1113. PMID: 30772097.
      Citations: 135     Fields:    Translation:Humans
    50. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr; 80(4):1029-1072. PMID: 30772098.
      Citations: 205     Fields:    Translation:Humans
    51. Strober BE, Gordon KB. Core Outcome Sets for Psoriasis Clinical Trials: Definition, Consensus, and Acceptance. JAMA Dermatol. 2018 10 01; 154(10):1135. PMID: 29874363.
      Citations:    Fields:    Translation:Humans
    52. Papp K, Gordon K, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S, Thaçi D. Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018 10 04; 379(14):1313-1321. PMID: 30205746.
      Citations: 135     Fields:    Translation:HumansCTClinical Trials
    53. Ibler E, Gordon KB. IL-23 inhibitors for moderate-to-severe psoriasis. Semin Cutan Med Surg. 2018 Sep; 37(3):158-162. PMID: 30215632.
      Citations: 4     Fields:    Translation:Humans
    54. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Papp KA, Sofen H, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Poulin Y, Puig L, Bachelez H. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 08 25; 392(10148):650-661. PMID: 30097359.
      Citations: 207     Fields:    Translation:HumansCTClinical Trials
    55. Kimball AB, Augustin M, Gordon KB, Krueger GG, Pariser D, Fakharzadeh S, Goyal K, Calabro S, Lee S, Lin R, Li N, Srivastava B, Guenther L. Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Br J Dermatol. 2018 10; 179(4):984-986. PMID: 29747219.
      Citations: 5     Fields:    Translation:Humans
    56. Gniadecki R, Leonardi CL, Gordon KB, Gu Y, Geng Z, Nader A, Teixeira HD. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018 Aug; 32(8):1297-1304. PMID: 29524255.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    57. Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Nov; 32(11):1940-1949. PMID: 29706008.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    58. Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol. 2018 06 01; 154(6):676-683. PMID: 29799960; PMCID: PMC6145649.
      Citations: 36     Fields:    Translation:Humans
    59. Baldwin HE, Stein Gold LF, Gordon KB, Green JB, Leonardi CL, Sengelmann RD. Highlights of Skin Disease Education Foundations 42nd Annual Hawaii Dermatology Seminar. Semin Cutan Med Surg. 2018 Jun; 37(4S):S75-S84. PMID: 30016379.
      Citations:    Fields:    
    60. Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018 08; 179(2):320-328. PMID: 29488226.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    61. Zachariae C, Gordon K, Kimball AB, Lebwohl M, Blauvelt A, Leonardi C, Braun D, McKean-Matthews M, Burge R, Cameron G. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2018 Aug; 79(2):294-301.e6. PMID: 29653208.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    62. Gordon KB, Armstrong AW, Menter MA, Wu JJ. Treating to Target-A Realistic Goal in Psoriasis? Semin Cutan Med Surg. 2018 Feb; 37(2S):S44-S47. PMID: 29614137.
      Citations: 4     Fields:    Translation:Humans
    63. Armstrong AW, Gordon KB, Menter MA, Wu JJ. The Evolving Landscape of Psoriasis Treatment. Semin Cutan Med Surg. 2018 Feb; 37(2S):S39-S43. PMID: 29614136.
      Citations: 4     Fields:    Translation:Humans
    64. Menter MA, Armstrong AW, Gordon KB, Wu JJ. Common and Not-So-Common Comorbidities of Psoriasis. Semin Cutan Med Surg. 2018 Feb; 37(2S):S48-S51. PMID: 29614138.
      Citations: 5     Fields:    Translation:Humans
    65. Wu JJ, Armstrong AW, Gordon KB, Menter MA. Practical Strategies for Optimizing Management of Psoriasis. Semin Cutan Med Surg. 2018 Feb; 37(2S):S52-S55. PMID: 29614139.
      Citations: 1     Fields:    Translation:Humans
    66. Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018 01; 178(1):132-139. PMID: 28940259.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    67. Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM. Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials. J Am Acad Dermatol. 2017 Dec; 77(6):1030-1037. PMID: 28993007.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    68. Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value Health. 2017 09; 20(8):1174-1179. PMID: 28964451.
      Citations: 1     Fields:    Translation:Humans
    69. Gordon KB, Leonardi CL, Furst DE, Bhatia N, Eichenfield LF, Beleznay K. Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminar™. Semin Cutan Med Surg. 2017 Jun; 36(4S):S52-S59. PMID: 28745729.
      Citations:    Fields:    
    70. Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Shrom D, Burge R, See K, Mallbris L, Gordon KB, Poulin Y. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017 Jun; 31(6):1004-1013. PMID: 28190255; PMCID: PMC5485049.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    71. Kathuria P, Gordon KB, Silverberg JI. Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures. J Am Acad Dermatol. 2017 Jun; 76(6):1045-1053.e3. PMID: 28314685.
      Citations: 30     Fields:    Translation:Humans
    72. Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar; 76(3):418-431. PMID: 28057361.
      Citations: 196     Fields:    Translation:HumansCTClinical Trials
    73. Gordon KB, Colombel JF, Hardin DS. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 11 24; 375(21):2102. PMID: 27959738.
      Citations: 23     Fields:    Translation:Humans
    74. Tan H, Valdez H, Griffins CE, Mrowietz U, Tallman A, Wolk R, Gordon K. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017 02; 28(1):3-7. PMID: 27538247.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    75. Hsu DY, Gordon K, Silverberg JI. Serious infections in hospitalized patients with psoriasis in the United States. J Am Acad Dermatol. 2016 Aug; 75(2):287-96. PMID: 27324314.
      Citations: 13     Fields:    Translation:Humans
    76. UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group, Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Jul 28; 375(4):345-56. PMID: 27299809.
      Citations: 248     Fields:    Translation:HumansCTClinical Trials
    77. Gordon KB. Translating the Science of Psoriasis. Semin Cutan Med Surg. 2016 Jun; 35(4 Suppl 4):S64. PMID: 27526392.
      Citations:    Fields:    Translation:HumansCells
    78. Armstrong AW, Lynde CW, McBride SR, Edson-Heredia E, Zhu B, Amato D, Yang FE, Gordon KB, Ståhle M, Nikaï E. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016 06 01; 152(6):661-9. PMID: 26953848.
      Citations: 18     Fields:    Translation:Humans
    79. Hsu DY, Gordon K, Silverberg JI. The inpatient burden of psoriasis in the United States. J Am Acad Dermatol. 2016 Jul; 75(1):33-41. PMID: 27210045.
      Citations: 6     Fields:    Translation:Humans
    80. Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, Gordon KB, Milmont CE, Viswanathan HN, Li J, Pinto L, Harrison DJ, Kricorian G, Nirula A, Klekotka P. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016 Jul; 75(1):77-82.e7. PMID: 27206759.
      Citations: 34     Fields:    Translation:Humans
    81. Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A, Lebwohl M. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015 Oct; 373(14):1318-28. PMID: 26422722.
      Citations: 246     Fields:    Translation:HumansCTClinical Trials
    82. Martin ML, Gordon K, Pinto L, Bushnell DM, Chau D, Viswanathan HN. The experience of pain and redness in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2015 Oct; 26(5):401-5. PMID: 25822169; PMCID: PMC4743609.
      Citations: 7     Fields:    Translation:Humans
    83. Duffin KC, Bissonnette R, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K, Gordon KB, Prinz JC. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015 Jul 09; 373(2):136-44. PMID: 26154787.
      Citations: 104     Fields:    Translation:HumansCTClinical Trials
    84. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul; 73(1):37-49. PMID: 26089047.
      Citations: 152     Fields:    Translation:HumansCTClinical Trials
    85. Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, Heffernan MP, Gordon KB, Leonardi CL. A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. J Eur Acad Dermatol Venereol. 2016 May; 30(5):864-5. PMID: 25773781.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    86. Gordon KB. Update on New and Emerging Therapies in the Management of Psoriasis. Semin Cutan Med Surg. 2015 Mar; 34(2 Suppl):S34-6. PMID: 26623549.
      Citations: 1     Fields:    
    87. Mercy KM, Gordon KB, Paller AS. Patient satisfaction and quality of life in psoriasis and psoriatic arthritis. JAMA. 2014 Dec 24-31; 312(24):2676-7. PMID: 25536259.
      Citations: 2     Fields:    Translation:Humans
    88. Gordon KB, Gottlieb AB, Langely RG, van de Kerkhof P, Belasco KT, Sundaram M, Okun M, Serra L. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. J Eur Acad Dermatol Venereol. 2015 Apr; 29(4):767-76. PMID: 25284275.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    89. Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014 Dec; 71(6):1176-82. PMID: 25242558.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    90. van de Kerkhof PC, Gordon KB, Kragballe K. Unmet needs in the treatment of psoriasis. Eur J Dermatol. 2014 Sep-Oct; 24(5):523-32. PMID: 25115238.
      Citations: 12     Fields:    Translation:Humans
    91. Kimball AB, Chau D, Viswanathan HN, Li J, Revicki DA, Kricorian G, Ortmeier BG, Gordon KB. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol. 2014 Mar; 170(3):705-15. PMID: 24079852; PMCID: PMC4153951.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    92. Gordon KB, Strober BE. Understanding therapeutic pathways and comorbidities in psoriasis. Semin Cutan Med Surg. 2014 Mar; 33(2 Suppl 2):S20-3. PMID: 24979540.
      Citations: 3     Fields:    Translation:Humans
    93. Leonardi CL, Gordon KB. New and emerging therapies in psoriasis. Semin Cutan Med Surg. 2014 Mar; 33(2 Suppl 2):S37-41. PMID: 24979544.
      Citations: 4     Fields:    Translation:Humans
    94. Zhu B, Edson-Heredia E, Cameron GS, Shen W, Erickson J, Shrom D, Wang P, Banerjee S, Gordon KB. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013 Dec; 169(6):1337-41. PMID: 24032554.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    95. Blauvelt A, Brown M, Gordon KB, Kavanaugh A, Leonardi CT, Stockfleth E, Strober B, Swanson NA, Martin G. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. J Clin Aesthet Dermatol. 2013 Sep; 6(9 Suppl):S2-S20. PMID: 24167640; PMCID: PMC3809592.
      Citations: 3     
    96. Lingam P, Nwe S, Gordon KB. Systemics to topicals in psoriasis: the unfilled need. Br J Dermatol. 2013 Jul; 169(1):2-3. PMID: 23834112.
      Citations:    Fields:    Translation:Humans
    97. Nwe SM, Champlain AH, Gordon KB. Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Rev Clin Immunol. 2013 Jul; 9(7):677-82. PMID: 23899238.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    98. Martin ML, McCarrier KP, Chiou CF, Gordon K, Kimball AB, Van Voorhees AS, Gottlieb AB, Huang X, Globe D, Chau D, Viswanathan HN, Kricorian G. Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. J Dermatolog Treat. 2013 Aug; 24(4):255-60. PMID: 23249143.
      Citations: 10     Fields:    Translation:Humans
    99. Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB, PHOENIX 1 Investigators. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec; 27(12):1535-45. PMID: 23279003.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    100. Bushnell DM, Martin ML, McCarrier K, Gordon K, Chiou CF, Huang X, Ortmeier B, Kricorian G. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013 Oct; 24(5):356-60. PMID: 23092173.
      Citations: 13     Fields:    Translation:Humans
    101. Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013 Oct; 27(10):1252-61. PMID: 23157612.
      Citations: 27     Fields:    Translation:Humans
    102. Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP, Burmester GR. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013 Apr; 72(4):517-24. PMID: 22562972; PMCID: PMC3595151.
      Citations: 187     Fields:    Translation:Humans
    103. Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012 Apr; 166(4):861-72. PMID: 22356258.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    104. Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatol Ther (Heidelb). 2012 Dec; 2(1):2. PMID: 23205325; PMCID: PMC3510406.
      Citations: 1     
    105. Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb). 2012 Dec; 2(1):1. PMID: 23205324; PMCID: PMC3510391.
      Citations: 4     
    106. Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu MC, Lebwohl M, Gordon KB, PHOENIX 1, PHOENIX 2, and ACCEPT investigators. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012 Mar; 11(3):300-12. PMID: 22395580.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    107. Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012 Feb; 132(2):304-14. PMID: 22011907.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    108. Pariser DM, Leonardi CL, Gordon K, Gottlieb AB, Tyring S, Papp KA, Li J, Baumgartner SW. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol. 2012 Aug; 67(2):245-56. PMID: 22015149.
      Citations: 17     Fields:    Translation:Humans
    109. Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, Yeilding N, Szapary PO, Fakharzadeh S, Li S, Hsu MC, Reich K. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012 May; 66(5):742-51. PMID: 21978572.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    110. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 Aug 24; 306(8):864-71. PMID: 21862748.
      Citations: 81     Fields:    Translation:Humans
    111. Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012 Feb; 66(2):241-51. PMID: 21752491.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    112. Gottlieb AB, Gordon K, Giannini EH, Mease P, Li J, Chon Y, Maddox J, Weng HH, Wajdula J, Lin SL, Baumgartner SW. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol. 2011 Mar; 10(3):289-300. PMID: 21369647.
      Citations: 14     Fields:    Translation:Humans
    113. American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul; 65(1):137-74. PMID: 21306785.
      Citations: 124     Fields:    Translation:Humans
    114. Kimball AB, Gordon KB, Langley RG, Menter A, Perdok RJ, Valdes J, ABT-874 Study Investigators. Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol. 2011 Feb; 64(2):263-74. PMID: 21145618.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    115. Krulig E, Gordon KB. Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid. 2010 Jul 27; 5:11-22. PMID: 20694136; PMCID: PMC2915500.
      Citations: 5     
    116. Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010 Sep; 63(3):448-56. PMID: 20605254.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    117. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep; 63(3):457-65. PMID: 20462664.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    118. Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg. 2010 Mar; 29(1):48-52. PMID: 20430307.
      Citations: 27     Fields:    Translation:Humans
    119. Gordon KB, Gandhi M. Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul. Arch Dermatol. 2010 Feb; 146(2):186-8. PMID: 20157030.
      Citations:    Fields:    Translation:Humans
    120. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JYM, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010 Jan; 62(1):114-135. PMID: 19811850.
      Citations: 75     Fields:    Translation:HumansCells
    121. Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009 Sep-Oct; 22(5):431-40. PMID: 19845720.
      Citations: 11     Fields:    Translation:Humans
    122. Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol. 2009 Jul; 61(1 Suppl 1):S1-S46. PMID: 19527820.
      Citations: 3     Fields:    Translation:Humans
    123. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009 Sep; 61(3):451-85. PMID: 19493586.
      Citations: 105     Fields:    Translation:Humans
    124. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R, American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009 Apr; 60(4):643-59. PMID: 19217694.
      Citations: 119     Fields:    Translation:Humans
    125. Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM, Jarratt MT, Krueger JG, Ridker PM, Stone N, Roberts WC. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol. 2008 Dec 15; 102(12):1631-43. PMID: 19064017.
      Citations: 41     Fields:    Translation:Humans
    126. Kazanis M, Leonardi C, Gordon K, Strober B, Menter A, Kimball AB. Rethinking eligibility creep. J Am Acad Dermatol. 2008 Jul; 59(1):165-7; author reply 167. PMID: 18571602.
      Citations:    Fields:    Translation:Humans
    127. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17; 371(9625):1665-74. PMID: 18486739.
      Citations: 436     Fields:    Translation:HumansCTClinical Trials
    128. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May; 58(5):826-50. PMID: 18423260.
      Citations: 307     Fields:    Translation:Humans
    129. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May; 58(5):851-64. PMID: 18423261.
      Citations: 111     Fields:    Translation:Humans
    130. Friedewald VE, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC. The editor's roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol. 2008 Apr 15; 101(8):1119-26. PMID: 18394444.
      Citations: 4     Fields:    Translation:Humans
    131. Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Ther Clin Risk Manag. 2008 Apr; 4(2):345-51. PMID: 18728850; PMCID: PMC2504074.
      Citations: 17     
    132. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG, National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008 Jun; 58(6):1031-42. PMID: 18313171; PMCID: PMC3716382.
      Citations: 100     Fields:    Translation:Humans
    133. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008 Feb; 144(2):200-7. PMID: 18283176.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    134. Gordon KB, Satoskar R. Therapeutics and immune-mediated skin disease. Curr Dir Autoimmun. 2008; 10:359-72. PMID: 18460896.
      Citations:    Fields:    Translation:Humans
    135. Langley RG, Gordon KB. Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol. 2007 Dec; 6(12):1205-12. PMID: 18189060.
      Citations: 2     Fields:    Translation:Humans
    136. Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008 Jan; 58(1):94-105. PMID: 17980456.
      Citations: 17     Fields:    Translation:HumansPHPublic Health
    137. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan; 58(1):106-15. PMID: 17936411.
      Citations: 178     Fields:    Translation:HumansCTClinical Trials
    138. Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci. 2007 Nov; 48(2):87-101. PMID: 17689932; PMCID: PMC2703191.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    139. Melhis SL, Gordon KB. The new psoriasis pathway: toward a unified theory of immunopathogenesis. Expert Rev Clin Immunol. 2007 Jul; 3(4):447-50. PMID: 20477148.
      Citations:    Fields:    
    140. Horn E, Gordon K, Mease P. The first World Psoriasis and Psoriatic Arthritis Conference. J Invest Dermatol. 2007 Jul; 127(7):1566-7. PMID: 17568796.
      Citations:    Fields:    Translation:Humans
    141. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007 Jun; 143(6):719-26. PMID: 17576937.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    142. Toor AA, Stiff PJ, Nickoloff BJ, Rodriguez T, Klein JL, Gordon KB. Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat. 2007; 18(1):13-8. PMID: 17365261.
      Citations: 3     Fields:    Translation:HumansCells
    143. Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007; 18(6):341-50. PMID: 18058494.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    144. Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007 Apr; 56(4):598-603. PMID: 17113190.
      Citations: 22     Fields:    Translation:Humans
    145. Nickoloff BJ, Bonish BK, Marble DJ, Schriedel KA, DiPietro LA, Gordon KB, Lingen MW. Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J Investig Dermatol Symp Proc. 2006 Sep; 11(1):16-29. PMID: 17069007.
      Citations: 23     Fields:    Translation:HumansCells
    146. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006 Oct; 55(4):598-606. PMID: 17010738.
      Citations: 104     Fields:    Translation:Humans
    147. Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A, Efalizumab Study Group. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol. 2006 May; 45(5):605-14. PMID: 16700803.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    148. Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, Leonardi CL, Efalizumab Study Group. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol. 2006 Apr; 54(4 Suppl 1):S164-70. PMID: 16488338.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    149. Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol. 2006 Mar; 54(3 Suppl 2):S85-91. PMID: 16488334.
      Citations: 10     Fields:    Translation:Humans
    150. Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006 Mar; 54(3 Suppl 2):S101-11. PMID: 16488320.
      Citations: 16     Fields:    Translation:Humans
    151. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006 Jan 07; 367(9504):29-35. PMID: 16399150.
      Citations: 338     Fields:    Translation:Humans
    152. Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, Zitnik R. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat. 2006; 17(1):9-17. PMID: 16467018.
      Citations: 24     Fields:    Translation:Humans
    153. Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. J Cutan Med Surg. 2005 Dec; 9(6):303-12. PMID: 16699904.
      Citations: 4     Fields:    Translation:Humans
    154. Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol. 2005 Nov; 153(5):945-53. PMID: 16225604.
      Citations: 12     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    155. Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, Wetherill G, Gordon KB. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther. 2005 Sep; 27(9):1317-28. PMID: 16291408.
      Citations: 5     Fields:    Translation:Humans
    156. Quinn AM, Brown K, Bonish BK, Curry J, Gordon KB, Sinacore J, Gamelli R, Nickoloff BJ. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005 Jun; 141(6):683-7. PMID: 15967913.
      Citations: 13     Fields:    Translation:Humans
    157. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005 May; 152(5):954-60. PMID: 15888152.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    158. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB, Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005 Mar; 52(3 Pt 1):425-33. PMID: 15761420.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    159. Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005 Jan; 141(1):82-4. PMID: 15655149.
      Citations: 13     Fields:    Translation:Humans
    160. Gordon KB. Patient education and advocacy groups: a means to better outcomes? Arch Dermatol. 2005 Jan; 141(1):80-1. PMID: 15655148.
      Citations: 1     Fields:    Translation:Humans
    161. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005 Jan; 141(1):31-8. PMID: 15655139.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    162. Gordon KB, Valentine J. The efficacy of alefacept in the treatment of chronic plaque psoriasis. J Cutan Med Surg. 2004 Dec; 8 Suppl 2:3-9. PMID: 15668749.
      Citations:    Fields:    Translation:Humans
    163. Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL, EFALIZUMAB STUDY GROUP. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol. 2004 Nov-Dec; 3(6):614-24. PMID: 15624744.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    164. Mehlis S, Gordon KB. From laboratory to clinic: rationale for biologic therapy. Dermatol Clin. 2004 Oct; 22(4):371-7, vii-viii. PMID: 15450333.
      Citations: 4     Fields:    Translation:HumansCells
    165. Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004; 17(5):427-31. PMID: 15379777.
      Citations: 9     Fields:    Translation:Humans
    166. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A, Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17; 290(23):3073-80. PMID: 14679270.
      Citations: 74     Fields:    Translation:HumansCellsCTClinical Trials
    167. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003 Dec; 139(12):1540-2. PMID: 14676068.
      Citations: 5     Fields:    Translation:Humans
    168. Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A, Alefacept Clinical Study Group. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol. 2003 Dec; 139(12):1563-70. PMID: 14676071.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    169. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2003 Dec; 2(6):624-8. PMID: 14711140.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    170. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003 Dec; 139(12):1627-32; discussion 1632. PMID: 14676082.
      Citations: 82     Fields:    Translation:HumansCTClinical Trials
    171. Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, Roberts JL, Washenik K, Vaishnaw AK, Gordon KB. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol. 2003 Nov; 49(5):816-25. PMID: 14576659.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    172. Gordon KB, McCormick TS. Evolution of biologic therapies for the treatment of psoriasis. Skinmed. 2003 Sep-Oct; 2(5):286-94. PMID: 14673261.
      Citations: 1     Fields:    Translation:HumansCells
    173. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003 Aug; 49(2 Suppl):S44-50. PMID: 12894125.
      Citations: 16     Fields:    Translation:HumansCells
    174. Gohari S, Gambla C, Healey M, Spaulding G, Gordon KB, Swan J, Cook B, West DP, Lapiere JC. Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgery. Dermatol Surg. 2002 Dec; 28(12):1107-14; discussion 1114. PMID: 12472488.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    175. Girvin AM, Gordon KB, Welsh CJ, Clipstone NA, Miller SD. Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cells. Blood. 2002 May 15; 99(10):3692-701. PMID: 11986225.
      Citations: 15     Fields:    Translation:AnimalsCells
    176. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol. 2002 May; 138(5):657-63. PMID: 12020229.
      Citations: 10     Fields:    Translation:HumansCells
    177. McClure SL, Valentine J, Gordon KB, McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf. 2002; 25(13):913-27. PMID: 12381213.
      Citations: 11     Fields:    Translation:Humans
    178. Robinson N, Singri P, Gordon KB. Safety of the new macrolide immunomodulators. Semin Cutan Med Surg. 2001 Dec; 20(4):242-9. PMID: 11770911.
      Citations: 4     Fields:    Translation:Humans
    179. Horn MA, Gordon KB. Chemoprevention of skin cancer. Cancer Treat Res. 2001; 106:255-82. PMID: 11225006.
      Citations:    Fields:    Translation:Humans
    180. Lapiere JC, Hirsh A, Gordon KB, Cook B, Montalvo A. Botulinum toxin type A for the treatment of axillary Hailey-Hailey disease. Dermatol Surg. 2000 Apr; 26(4):371-4. PMID: 10759827.
      Citations: 9     Fields:    Translation:Humans
    181. Wang C, Quevedo ME, Lannutti BJ, Gordon KB, Guo D, Sun W, Paller AS. In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. J Invest Dermatol. 1999 May; 112(5):775-81. PMID: 10233771.
      Citations: 5     Fields:    Translation:AnimalsCells
    182. Ward SK, Roenigk HH, Gordon KB. Dermatologic manifestations of gastrointestinal disorders. Gastroenterol Clin North Am. 1998 Sep; 27(3):615-36, vi. PMID: 9891700.
      Citations: 3     Fields:    Translation:Humans
    183. Tan L, Gordon KB, Mueller JP, Matis LA, Miller SD. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes. J Immunol. 1998 May 01; 160(9):4271-9. PMID: 9574529.
      Citations: 32     Fields:    Translation:AnimalsCells
    184. Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, Wojnarowska F, Stevens SR, Chen M, Fairley JA, Woodley DT, Miller SD, Gordon KB. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol. 1998 Feb; 110(2):103-9. PMID: 9457902.
      Citations: 66     Fields:    Translation:HumansAnimals
    185. Gordon KB, Roenigk HH, Gendleman M. Treatment of multiple lesions of Bowen disease with isotretinoin and interferon alfa. Efficacy of combination chemotherapy. Arch Dermatol. 1997 Jun; 133(6):691-3. PMID: 9197821.
      Citations: 2     Fields:    Translation:Humans
    186. Gordon KB, Chan LS, Woodley DT. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol. 1997 Mar; 136(3):415-20. PMID: 9115929.
      Citations: 16     Fields:    Translation:HumansCells
    187. Nikcevich KM, Gordon KB, Tan L, Hurst SD, Kroepfl JF, Gardinier M, Barrett TA, Miller SD. IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. J Immunol. 1997 Jan 15; 158(2):614-21. PMID: 8992975.
      Citations: 42     Fields:    Translation:AnimalsCells
    188. Katz SK, Gordon KB, Roenigk HH. The cutaneous manifestations of gastrointestinal disease. Prim Care. 1996 Sep; 23(3):455-76. PMID: 8888338.
      Citations: 1     Fields:    Translation:Humans
    189. Gordon KB, Garden JM, Robinson JK. Bowen's disease of the distal digit. Outcome of treatment with carbon dioxide laser vaporization. Dermatol Surg. 1996 Aug; 22(8):723-8. PMID: 8780766.
      Citations: 4     Fields:    Translation:Humans
    190. Gordon KB, Guitart J, Kuzel T, Salard D, Bakouche O, Domer P, Roenigk H, Rosen S. Pseudo-mycosis fungoides in a patient taking clonazepam and fluoxetine. J Am Acad Dermatol. 1996 Feb; 34(2 Pt 1):304-6. PMID: 8642101.
      Citations: 3     Fields:    Translation:Humans
    191. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer. 1995 Apr 15; 75(8):2169-73. PMID: 7697608.
      Citations: 27     Fields:    Translation:Humans
    192. Gordon KB, Robinson J. Carbon dioxide laser vaporization for Bowen's disease of the finger. Arch Dermatol. 1994 Oct; 130(10):1250-2. PMID: 7944505.
      Citations: 3     Fields:    Translation:Humans
    193. Peterson K, Gordon KB, Heinemann MH, DeAngelis LM. The clinical spectrum of ocular lymphoma. Cancer. 1993 Aug 01; 72(3):843-9. PMID: 8334638.
      Citations: 59     Fields:    Translation:Humans
    Gordon's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (456)
    Explore
    _
    Co-Authors (3)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _